We are delighted to announce a new charity partnership with Stirling Business Solutions. Stirling are business transfer specialists and business brokers based in Birmingham. Their main purpose is to find buyers for businesses for sale and to seek out acquisitions for buyers and investors. Their wealth of experience coupled with effective and proven marketing services help provide potential buyers quickly, in order to meet their objective of finding six potential buyers within three months, for their clients.
Stirling join an ever-growing list of influential businesses who are recognising the fantastic work being done by Cure Leukaemia co-founder Professor Charlie Craddock and his teams based in the Centre for Clinical Haematology at the Queen Elizabeth Hospital and across the West Midlands.
Mark Pilsbury, Director at Stirling Business Solutions, said:
“We are delighted to become an official charity partner of Cure Leukaemia. In 1996, my wife was diagnosed with Acute Myeloid Leukaemia (AML) and after six months of intensive treatment and five years in remission she was given the all clear in 2001. We will always be eternally grateful to the amazing team of Haematoligists that helped my wife and are determined to help as many other people as possible. Having met with James McLaughlin and Professor Charlie Craddock, we were so impressed at what Cure Leukaemia are doing that we felt compelled to be involved in helping to raise more awareness and as much money as possible to assist them in helping beat this terrible disease”.
Chief Executive of Cure Leukaemia James McLaughlin said:
“We are thrilled to welcome Stirling into the Cure Leukaemia family, adding to the list of influential Birmingham businesses backing the work of the charity. With Stirling’s connections I am sure it will open many doors for Cure Leukaemia and I hope too, that it can be a mutually beneficial relationship.
Stirling’s enthusiasm to help fundraise, promote and grow the charity has been evident and I look forward to working with them."
Cure Leukaemia's £1m Centre Appeal 2017